Peter Wiklund, a surgeon who pioneered robot-assisted cystectomy, has been appointed director of the Bladder Cancer Program at the Mount Sinai Health System and professor of urology in the Department of Urology at the Icahn School of Medicine at Mount Sinai.
On Aug. 26, FDA approved the RAS inhibitor, daraxonrasib, sponsored by Revolution Medicines Inc. and also known as Rasonque, for patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
